EUVIMEDEUVIMED entdecken
Crossref

Anticoagulant treatment and COVID-19

İbrahim Halil ÖZDEMIR, Mehmet Burak ÖZEN, Ramazan GÜNDÜZ

Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi · 2022

DOI: 10.34087/cbusbed.1007918 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi, 2022. Verfasst von İbrahim Halil ÖZDEMIR und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: yok.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

In this study, we aimed to examine the effect of atrial fibrillation (AF) on mortality in COVID-19 patients and the risk scores that can be used in determining risky AF patients. In addition, we aimed to examine the place of oral anticoagulant use in treatment. Materials and Methods: Records of patients diagnosed with COVID-19 were retrospectively reviewed. Among these patients, 48 patients with a diagnosis of AF were identified. Intensive care need, mortality, CHA2DS2VASC and HAS-BLED scores of the patients were recorded. CRP and D-Dimer levels were recorded. Oral anticoagulant treatments used by the patients were recorded.

Results

The CHA2DS2VASC (intensive care: 4,50±1,41, internal medicine service: 2,50±1,05, p

Förderung

  • yok

Zitieren

APA

ÖZDEMIR, İ. H., ÖZEN, M. B., & GÜNDÜZ, R. (2022). Anticoagulant treatment and COVID-19. Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi. https://doi.org/10.34087/cbusbed.1007918

Vancouver

ÖZDEMIR İH, ÖZEN MB, GÜNDÜZ R. Anticoagulant treatment and COVID-19. Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi. 2022. doi:10.34087/cbusbed.1007918

BibTeX
@article{ZDEMIR2022,
  author = {ÖZDEMIR, İbrahim Halil and ÖZEN, Mehmet Burak and GÜNDÜZ, Ramazan},
  title = {Anticoagulant treatment and COVID-19},
  journal = {Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi},
  year = {2022},
  doi = {10.34087/cbusbed.1007918}
}
Kostenlos starten →